Literature DB >> 23450376

Evaluation of polyhexamethylene biguanide (PHMB) as a disinfectant for adenovirus.

Eric G Romanowski1, Kathleen A Yates, Katherine E O'Connor, Francis S Mah, Robert M Q Shanks, Regis P Kowalski.   

Abstract

IMPORTANCE: Swimming pools can be a vector for transmission of adenovirus ocular infections. Polyhexamethylene biguanide (PHMB) is a disinfectant used in swimming pools and hot tubs.
OBJECTIVE: To determine whether PHMB is an effective disinfectant against ocular adenovirus serotypes at a concentration used to disinfect swimming pools and hot tubs.
DESIGN: In vitro laboratory study.
INTERVENTIONS: The direct disinfecting activity of PHMB was determined in triplicate assays by incubating 9 human adenovirus types (1, 2, 3, 4, 5, 7a, 8, 19, and 37) with PHMB concentrations of 50 and 0 ppm (micrograms per milliliter) for 24 hours at room temperature to simulate swimming pool temperatures or 40oC to simulate hot tub temperatures. MAIN OUTCOME MEASURES: Plaque assays were performed to determine adenovirus titers after incubation. Titers were log10 converted and mean (SD) log10 reductions relative to controls were calculated. Virucidal (>99.9%) decreases in mean adenovirus titers after PHMB treatment were determined for each adenovirus type and temperature tested. RESULTS At room temperature, 50 ppm of PHMB produced mean reductions in titers less than 1 log10 for all adenovirus types tested. At 40°C, 50 ppm of PHMB produced mean reductions in titers less than 1 log10 for 2 adenovirus types and greater than 1 but less than 3 log10 for 7 of 9 adenovirus types. CONCLUSIONS AND RELEVANCE: At a concentration of 50 ppm, PHMB was not virucidal against adenovirus at temperatures consistent with swimming pools or hot tubs. Recreational water maintained and sanitized with PHMB can serve as a vector for the transmission of ocular adenovirus infections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23450376      PMCID: PMC3625491          DOI: 10.1001/jamaophthalmol.2013.2498

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  21 in total

1.  Feasibility of an antiviral clinical trial requiring cross-country shipment of conjunctival adenovirus cultures and recovery of infectious virus.

Authors:  Eric G Romanowski; Stephen P Bartels; Roger Vogel; Neal T Wetherall; Cheryl Hodges-Savola; Regis P Kowalski; Kathleen A Yates; Paul R Kinchington; Y Jerold Gordon
Journal:  Curr Eye Res       Date:  2004 Aug-Sep       Impact factor: 2.424

2.  Adenovirus type 3 epidemic associated with intermittent chlorination of a swimming pool.

Authors:  H M Foy; M K Cooney; J B Hatlen
Journal:  Arch Environ Health       Date:  1968-11

3.  Prolonged recovery of desiccated adenoviral serotypes 5, 8, and 19 from plastic and metal surfaces in vitro.

Authors:  Y J Gordon; R Y Gordon; E Romanowski; T P Araullo-Cruz
Journal:  Ophthalmology       Date:  1993-12       Impact factor: 12.079

4.  Effects of swimming pool water on the cornea.

Authors:  J R Haag; R G Gieser
Journal:  JAMA       Date:  1983-05-13       Impact factor: 56.272

5.  Community outbreak of adenovirus type 7a infections associated with a swimming pool.

Authors:  M Turner; G R Istre; H Beauchamp; M Baum; S Arnold
Journal:  South Med J       Date:  1987-06       Impact factor: 0.954

6.  Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide.

Authors:  D F Larkin; S Kilvington; J K Dart
Journal:  Ophthalmology       Date:  1992-02       Impact factor: 12.079

7.  Pharyngoconjunctival fever caused by adenovirus type 4: report of a swimming pool-related outbreak with recovery of virus from pool water.

Authors:  L J D'Angelo; J C Hierholzer; R A Keenlyside; L J Anderson; W J Martone
Journal:  J Infect Dis       Date:  1979-07       Impact factor: 5.226

8.  Sensitivity of human adenoviruses to different groups of chemical biocides.

Authors:  A Sauerbrei; K Sehr; A Brandstädt; A Heim; K Reimer; P Wutzler
Journal:  J Hosp Infect       Date:  2004-05       Impact factor: 3.926

9.  An outbreak of adenovirus type 3 disease at a private recreation center swimming pool.

Authors:  W J Martone; J C Hierholzer; R A Keenlyside; D W Fraser; L J D'Angelo; W G Winkler
Journal:  Am J Epidemiol       Date:  1980-02       Impact factor: 4.897

10.  Polyhexamethylene biguanide exposure leads to viral aggregation.

Authors:  F Pinto; J-Y Maillard; S P Denyer; P McGeechan
Journal:  J Appl Microbiol       Date:  2009-10-20       Impact factor: 3.772

View more
  8 in total

1.  Benzalkonium Chloride Demonstrates Concentration-Dependent Antiviral Activity Against Adenovirus In Vitro.

Authors:  Eric G Romanowski; Kathleen A Yates; Robert M Q Shanks; Regis P Kowalski
Journal:  J Ocul Pharmacol Ther       Date:  2019-04-10       Impact factor: 2.671

2.  Topical Antimicrobials in Burn Care: Part 1-Topical Antiseptics.

Authors:  Janos Cambiaso-Daniel; Stafanos Boukovalas; Genevieve H Bitz; Ludwik K Branski; David N Herndon; Derek M Culnan
Journal:  Ann Plast Surg       Date:  2018-01-09       Impact factor: 1.539

3.  A Comparison of the Effects of Topical Prolavacid Solution (a Polyhexamethylene Biguanide-Based Wound Cleanser) and Medihoney Ointment in a Rat Model of Cutaneous Wound.

Authors:  Shahram Paydar; Bijan Ziaeian; Amirreza Dehghanian; Mohsen Heidarpour; Roshanak Alavi Moghadam; Behnam Dalfardi; Abbas Hallaj Karladani
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-12-01       Impact factor: 4.730

4.  Acanthamoeba Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs.

Authors:  Brian Shing; Mina Balen; James H McKerrow; Anjan Debnath
Journal:  Expert Rev Anti Infect Ther       Date:  2021-05-19       Impact factor: 5.091

5.  Toxicological assessment of polyhexamethylene biguanide for water treatment.

Authors:  Isaac J Asiedu-Gyekye; Abdulai Seidu Mahmood; Charles Awortwe; Alexander K Nyarko
Journal:  Interdiscip Toxicol       Date:  2015-12

6.  SARS-CoV-2 decontamination of skin with disinfectants active during and after application.

Authors:  R K Campos; D Mirchandani; G Rafael; N Saada; R McMahon; S C Weaver
Journal:  J Hosp Infect       Date:  2021-02-10       Impact factor: 3.926

7.  The in vitro Evaluation of the Activity of COVID-19 Antiviral Drugs Against Adenovirus.

Authors:  Eric G Romanowski; Kathleen A Yates; John E Romanowski; Robert M Q Shanks; Regis P Kowalski
Journal:  Clin Ophthalmol       Date:  2021-12-22

Review 8.  Targeting the hard to reach: challenges and novel strategies in the treatment of intracellular bacterial infections.

Authors:  Nor Fadhilah Kamaruzzaman; Sharon Kendall; Liam Good
Journal:  Br J Pharmacol       Date:  2016-12-07       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.